ShareValue scores for PPLPHARMA.NSE: Valuation 56, Quality 30, Growth 32, Health 46.

PPLPHARMA.NSE
NSE

Piramal Pharma Limited

₹208.44(+0.80%)
Loading chart...
Sentiment

Verdicts

Rating

Trap Risk

Return

5% to 17%
Valuation
56
Fair Value
Price vs Value
Quality
30
Weak
Business Strength
Growth
32
Weak
Revenue & Earnings
Health
46
Moderate
Financial Stability
Momentum
33
Bearish
Price Trend

Company Details

About

Piramal Pharma Limited operates as a pharmaceutical company in the United States, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufacturing facilities and distribution network. It also operates contract development and manufacturing organization that provides services across the drug life cycle, including discovery, development, and commercial manufacturing of drug substances and products; offers inhalation anesthetics, intrathecal therapy, injectable pain and anesthesia drugs, and other generic and specialty products; and analgesics, skin care, vitamin/mineral supplement, kids' wellness, digestives, women's health, and hygiene, as well as adult incontinence. The company was incorporated in 2020 and is based in Mumbai, India.

Score Analysis

AI Investment Thesis

Data as of:Aug 7, 2026
|
Last calculated:Aug 7, 2026